CapyFin

Loading...

CapyFin Real-time Earnings Reports.

Products

Earnings
API

Get in Touch

Contact Us
X (Twitter)
LinkedIn

Resources

Privacy Policy
Terms of Service
Sign Up
Sign In

© 2025 CapyFin. All rights reserved.

Disclaimer: This platform provides information and recommendations for educational purposes only and is not a substitute for professional financial advice. Our content covers a range of investment classes, including stocks and cryptocurrencies, and we do not guarantee the completeness, accuracy, reliability, or suitability of this information, which may include data from third-party services and content generated by artificial intelligence (AI). Investing in stocks, cryptocurrencies, and other financial instruments involves risks, including the potential loss of principal. Users should independently verify all information and seek advice from qualified professionals tailored to their individual financial situations and investment objectives. Our content and services are provided "as is" without any warranties, express or implied. We are not liable for any losses or damages arising from the use of our services. This disclaimer is subject to change; users are advised to review it periodically. Usage of our services constitutes acceptance of these terms.

🇺🇸 NASDAQ:EVLO

Overview Earnings Dividends

Feb 13, 2020

•

Dec 31, 2019

Evelo Q4 2019 Earnings Report

Reported financial results and business highlights for Q4 and full year 2019.

Key Takeaways

Evelo Biosciences reported positive clinical data supporting the validation of its novel platform and demonstrating the targeting of SINTAX™ to drive clinical effects in individuals with psoriasis. Multiple clinical readouts are planned across the inflammation and oncology portfolio in 2020, and the development of EDP1815 is progressing.

Strong 2019 marked by clinical data that validates platform

Lead inflammation candidate EDP1815 showed positive clinical data across two separate cohorts

EDP1815 Phase 2 study initiation expected in Q2 2020

Multiple clinical readouts across inflammation and oncology portfolio expected throughout 2020

EPS

-$14

Previous year: -$9.8

+42.9%

Gross Profit

$0

0

Cash and Equivalents

$77.8M

Evelo

Evelo

Company Overview

Full financial data and analysis